Globus Medical (GMED) Is Up 7.4% After Q1 Beat And AI-Driven Margin Expansion Push - What's Changed

• Globus Medical recently reported a strong first quarter, beating earnings and revenue expectations, expanding adjusted EBITDA margins and raising full-year non-GAAP EPS guidance while maintaining revenue targets.
• These results, combined with the rollout of generative AI across its operations and ongoing integration of NuVasive and Nevro, highlight how technology and M&A are reshaping the company’s efficiency and growth profile.
• Now we’ll examine how this earnings beat and AI-driven efficiency push may influence Globus Medical’s existing investment narrative and risk balance.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Globus Medical Investment Narrative Recap

To own Globus Medical, you need to believe that its spine and enabling technologies, bolstered by NuVasive and Nevro, can convert innovation into durable earnings, not just one-off beats. The latest quarter’s margin expansion and raised EPS guidance strengthen the near term catalyst around AI driven efficiency, but they do not remove the biggest risk: that integrating recent acquisitions and higher cost bases, particularly at Nevro, could still weigh on margins if execution slips.

Among recent developments, the company’s broad rollout of generative AI across product development, sales enablement, and clinical support stands out as most relevant. It directly ties into the earnings beat by aiming to improve productivity and support higher margin, recurring revenue from robotics and other enabling technologies, while also testing whether these digital tools can offset ongoing pressures around extended sales cycles, competition, and integration complexity.

Yet despite the strong quarter, investors should be aware that persistent integration and cost risks could still pressure margins if...

Read the full narrative on Globus Medical (it's free!)

Globus Medical's narrative projects $3.7 billion revenue and $641.5 million earnings by 2029. This requires 5.7% yearly revenue growth and about a $54.8 million earnings increase from $586.7 million today.

Uncover how Globus Medical's forecasts yield a $111.50 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts sound far more cautious, assuming revenue of about US$3.4 billion and earnings near US$462 million by 2028, and arguing that today’s strong AI and M&A story could still be tested by slower enabling tech adoption and tighter margins, which is worth weighing against more optimistic views as you compare different scenarios after this new earnings beat.

Explore 5 other fair value estimates on Globus Medical - why the stock might be worth as much as 83% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Globus Medical research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Globus Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globus Medical's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 48 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com